Evotec (EVO) announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis, following four earlier TB grants from the foundation, amounting to $4.9M over 25 months and $5M over 24 months. The grant programs will expand the pipeline of TB drug candidates and advance the most promising combinations toward clinical evaluation, reducing development risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVO:
- Evotec Announces CFO Transition as Hitchin Departs and Hinshelwood Steps In
- Evotec CFO Paul Hitchin to step down, Claire Hinshelwood to succeed
- Evotec assumed with a Buy at H.C. Wainwright
- Evotec appoints Ingrid Muller as COO
- Limited Near-Term Visibility and Execution Risk Drive Sell Rating on Evotec Despite In-Line Results